FAM196A inhibitors encompass a specialized class of chemical compounds designed to selectively impede the activity of the FAM196A protein, a factor implicated in various cellular processes. These inhibitors operate through a myriad of mechanisms, each tailored to target the unique interactions and pathways involving FAM196A. Some inhibitors in this class might directly bind to the active sites or allosteric sites on the FAM196A protein, thereby obstructing its functional conformation and subsequent biological activity. Others may act indirectly, influencing the regulatory pathways that control FAM196A's expression or its post-translational modifications, which are critical for its proper function. For instance, compounds that hinder the phosphorylation of FAM196A can prevent its activation or the recruitment of requisite binding partners, leading to a cascade of inhibited cellular responses. These inhibitors may also impede the protein's ability to engage with DNA, RNA, or other proteins, depending on the specific role FAM196A plays within the cell. The design of these inhibitors takes into account the intricate structure of FAM196A, ensuring that the binding of the inhibitor induces a conformational change that reduces the protein's activity.
Inhibitors of FAM196A also modulate the protein's interaction within its signaling networks. By disrupting the delicate equilibrium of protein-protein interactions, these inhibitors can lead to a reduction in the propagation of signals that rely on FAM196A's mediation. This might involve hindering the protein's capacity to act as a scaffold in multiprotein complexes or preventing its role in the assembly of signaling clusters essential for the transduction of certain cellular signals. Moreover, some inhibitors might target the degradation pathways of FAM196A, such as the ubiquitin-proteasome system, thereby amplifying the degradation rate and reducing the overall protein levels within the cell. The strategic inhibition can result from stabilizing negative regulators of FAM196A or by mimicking the action of natural inhibitors within the cell, ultimately leading to a decrease in the functional activity of FAM196A. The precise modulation of these interactions by the inhibitors is key to the control of FAM196A's involvement in the cellular context, ensuring that its activity remains tightly regulated and does not exceed its normal physiological parameters.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR, which is a part of the PI3K/AKT pathway. FAM196A, when expressed, may be involved in downstream signaling of this pathway. Inhibition of mTOR could reduce the functional activity of FAM196A if it is regulated by or interacts with components of this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3K). PI3K is upstream of AKT signaling which may affect the phosphorylation status and function of FAM196A if it is a downstream effector in this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another potent inhibitor of PI3K, leading to a blockade of the PI3K/AKT signaling pathway. As with wortmannin, inhibiting PI3K would decrease AKT activity potentially leading to decreased function of FAM196A if it is modulated by AKT. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically inhibits the phosphorylation of AKT, which is a key player in signaling pathways that regulate cell survival and proliferation. Inhibition of AKT activation would alter the functional activity of FAM196A if it is an AKT substrate. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, leading to suppression of the ERK/MAPK pathway. If FAM196A requires MAPK signaling for its activity, MEK inhibition would result in reduced activity of FAM196A. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 selectively inhibits MEK, which in turn decreases ERK pathway activity. As with U0126, this would lead to reduced FAM196A activity if its function is dependent on the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, the inhibitor could reduce the activity of FAM196A if it is regulated by or interacts with the p38 MAPK signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can modulate cellular apoptosis and survival. If FAM196A is connected to JNK signaling, inhibition by SP600125 could decrease its activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Src kinases can influence multiple signaling pathways, including those regulating cytoskeletal dynamics. If FAM196A is associated with these pathways, its activity could be diminished by dasatinib. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
Imatinib mesylate inhibits Bcr-Abl tyrosine kinase as well as other kinases like c-Kit. If FAM196A functionally interacts with these kinases, inhibition by imatinib could lead to decreased activity of FAM196A. | ||||||